Blueprint Medicines (NASDAQ:BPMC) Lifted to “Strong-Buy” at Baird R W
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was upgraded by stock analysts at Baird R W to a “strong-buy” rating in a research report issued to clients and investors on Friday, Zacks.com reports. BPMC has been the topic of a number of other reports. Barclays upped their price target on Blueprint Medicines from $75.00 to […]
More Stories
PVH Corp. (NYSE:PVH) Shares Sold by Public Employees Retirement System of Ohio
Public Employees Retirement System of Ohio lowered its stake in PVH Corp. (NYSE:PVH – Free Report) by 6.3% in the...
Promising Streaming Stocks To Follow Today – May 31st
NVIDIA, AppLovin, Spotify Technology, Walt Disney, Comcast, Live Nation Entertainment, and Take-Two Interactive Software are the seven Streaming stocks to...
Large Cap Stocks To Follow Today – May 31st
NVIDIA, Tesla, and Invesco QQQ are the three Large Cap stocks to watch today, according to MarketBeat’s stock screener tool....
Top Automotive Stocks To Watch Now – May 30th
NVIDIA, Tesla, and Costco Wholesale are the three Automotive stocks to watch today, according to MarketBeat’s stock screener tool. Automotive...
Man Throws Firebombs at Pro-Israel Demonstrators in Colorado, 6 Injured
By Joseph Lord The FBI has named the suspect in a violent attack in Boulder, Colorado, as 45-year-old Mohamed Sabry...
Taylor Swift Big Win, Claims Back Her Earliest Albums
Mega Pop Star, Taylor Swift has reached a significant milestone of her career as she has reacquired the master recordings...